ARUP LABORATORIES | aruplab.com
500 Chipeta Way, Salt Lake City, Utah 84108-1221
phone: 801-583-2787, toll free: 800-522-2787
Jonathan R. Genzen, MD, PhD, Chief Medical Officer

PATIENT REPORT

Patient Age/Sex: Male

Specimen Collected: 08-Dec-22 13:39

CIC (19q13.2) Gene Rearrangement by FISH | **Received: 08-Dec-22 13:39** | **Report/Verified: 08-Dec-22 13:41**

Procedure	Result	Units	Reference Interval
CIC FISH Result	Negative [f1 i1]		
Total Cell Count	1234		
Scoring Method	Manual		
CIC FISH Reference Number	ABC-1234		
CIC FISH Source	ABCD		

Result Footnote

f1: CIC FISH Result
Controls were run and performed as expected.
This result has been reviewed and approved by [redacted]

Test Information

i1: CIC FISH Result
INTERPRETIVE INFORMATION: CIC (19q13), FISH

Fluorescence in situ hybridization (FISH) analysis was performed on a section from a paraffin-embedded tissue block using differentially labeled fluorescent probes targeting the upstream (5') and downstream (3') flanking regions of the CIC gene (Agilent Technologies). Cells were evaluated from regions of tumor identified on histopathologic review of a matching hematoxylin- and eosin-stained section. Controls performed appropriately.

This test is designed to detect rearrangements involving the CIC gene, but it does not identify a specific partner gene. An abnormal signal pattern seen in 25 percent or more of the tumor cells evaluated is considered a positive result. Based on the assay performance during test validation, the test is expected to detect 100 percent of CIC rearrangements in patients with CIC-rearranged sarcoma, except for rare instances of cryptic rearrangements. Assay range and limit of detection were generated using normal and known positive cases respectively. Identification of a rearrangement of the CIC gene locus is useful for the diagnosis of CIC-rearranged sarcoma. CIC rearrangements have also been reported in certain other tumors, including angiosarcoma and central nervous system tumors. Correlation with histopathologic and clinical findings is, therefore, essential for complete interpretation of this study.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.